Skip to content

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-519499-22-00
Enrollment
31
Registered
2025-06-27
Start date
2025-08-04
Completion date
Unknown
Last updated
2025-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or Metastatic Hepatocellular Carcinoma

Interventions

None listed

Sponsors

Alnylam Pharmaceuticals Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026